Lumida
/RXRX
⌘K
Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals Inc

RXRX
$3.20USD+1.27%+0.04 today

MARKET CAP

1.7B

P/E (TTM)

FWD P/E

DAY RANGE

$3 – $3

52W RANGE

$3
$7

AI Summary

Stalk
TrimMedium

RXRX has decisively broken below multi-week support around $3.30–3.33, confirming a bearish medium-term bias. Price trades below declining 9/20 EMAs and the 50 SMA, reinforcing downtrend pressure. The primary pattern “Support Failure” signals sellers are overwhelming buyers. Execution favors shorting rallies into the 3.30–3.35 resistance zone. Key risks include a short-squeeze relief bounce or reclaim of EMAs that would invalidate the bearish posture.

  • REC 4881 median polyp burden down 43% after three months in FAP trials
  • Generated over $500 M in partnership inflows from Roche Genentech and Sanofi
  • Q2 2026 revenue of $7.67 M fell short of expectations
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$10.2M$39.8M$44.6M$58.8M$74.7M
YoY %+291.5%+11.9%+32.0%+26.9%
P / Sales211.0x33.3x46.0x31.5x24.5x
EV / Sales189.6x24.9x41.5x28.4x19.1x
Gross Profit, Adj.$10.2M$-8.4M$2.0M$13.6M$3.7M
YoY %-182.8%+123.6%+584.2%-72.6%
Margin %100.0%-21.2%4.5%23.1%5.0%
EV / Gross Profit189.6x-117.5x930.7x123.0x383.6x
EBITDA, Adj.$-174.4M$-234.0M$-325.7M$-442.5M$-564.4M
YoY %-34.2%-39.2%-35.9%-27.6%
Margin %-1713.2%-587.2%-730.6%-752.1%-755.8%
EV / EBITDA-11.1x-4.2x-5.7x-3.8x-2.5x
EBIT$-182.8M$-245.7M$-350.1M$-479.0M$-648.1M
YoY %-34.4%-42.5%-36.8%-35.3%
Margin %-1795.8%-616.7%-785.3%-814.1%-867.9%
EV / EBIT-10.6x-4.0x-5.3x-3.5x-2.2x
Net Income$-186.5M$-239.5M$-328.1M$-463.7M$-644.8M
YoY %-28.4%-37.0%-41.3%-39.1%
Net Margin-1832.2%-601.0%-736.0%-788.0%-863.4%
EPS (GAAP)-$1.49-$1.36-$1.58-$1.69-$1.44
YoY %+8.7%-16.2%-7.0%+14.8%